Dual-Regulated Functionalized Liposome–Nanoparticle Hybrids Loaded with Dexamethasone/TGFβ1-siRNA for Targeted Therapy of Glomerulonephritis

Fang, Pengchao; Han, Lu; Liu, Chunping; Deng, Shichen; Zhang, E.; Gong, Puyang; Ren, Yan-Fang; Jian, Gu; He, Lili; Yuan, Zhixiang

doi:10.1021/acsami.1c20053

Cited by 11 publications

(8 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This liposomal formulation was functionalized with folic acid to target the breast cancer cells in vivo. 62 Apart from chemotherapeutic applications, liposome have also been investigated for other diseases like Glomerulonephritis, which is a disease associated with kidney inflammation. Fang et al have developed gold nanoparticle immunoliposomes (Au-ILs) and liposome-gold nanoparticle hybrids (Au-LNHy).…”

Section: Liposomes As a Therapeutic Carriermentioning

confidence: 99%

“…Apart from chemotherapeutic applications, liposome have also been investigated for other diseases like Glomerulonephritis, which is a disease associated with kidney inflammation. Fang et al have developed gold nanoparticle immunoliposomes (Au-ILs) and liposome-gold nanoparticle hybrids (Au-LNHy) . These were encapsulated with Dexamethasone/TGFβ1-siRNA.…”

Section: Liposomes As a Therapeutic Carriermentioning

confidence: 99%

“…Fang et al have developed gold nanoparticle immunoliposomes (Au-ILs) and liposome-gold nanoparticle hybrids (Au-LNHy). 63 These were encapsulated with Dexamethasone/TGFβ1-siRNA. In this study, Further to target the glomerular mesangial cell, α8 integrin antibodies were conjugated on the surface of the liposomes.…”

Section: Liposomes As a Therapeutic Carriermentioning

confidence: 99%

“…Their observation showed effective targeting of the liposomes in the mesangial cells (MCs) within the glomerulus and further release of drug lead to suppressing local inflammation and fibrosis, resulting in improved therapeutic outcomes ( Figure 1 ). 63 …”

Section: Liposomes As a Therapeutic Carriermentioning

confidence: 99%

“…(D) HE staining assay of mouse heart, liver, spleen, lung, and kidney tissue sections after administration of DXMS/siRNA, DXMS/siRNA@Au-LNHy, or DXMS/siRNA@Au-ILs for analyzing in vivo toxicity. Adapted with permission from ref ( 63 ). Copyright 2021 American Chemical Society.…”

Section: Liposomes As a Therapeutic Carriermentioning

confidence: 99%

See 4 more Smart Citations

Liposomes to Cubosomes: The Evolution of Lipidic Nanocarriers and Their Cutting-Edge Biomedical Applications

Attri,

Das,

Banerjee

et al. 2024

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Lipidic nanoparticles have undergone extensive research toward the exploration of their diverse therapeutic applications. Although several liposomal formulations are in the clinic (e.g., DOXIL) for cancer therapy, there are many challenges associated with traditional liposomes. To address these issues, modifications in liposomal structure and further functionalization are desirable, leading to the emergence of solid lipid nanoparticles and the more recent liquid lipid nanoparticles. In this context, "cubosomes", third-generation lipidic nanocarriers, have attracted significant attention due to their numerous advantages, including their porous structure, structural adaptability, high encapsulation efficiency resulting from their extensive internal surface area, enhanced stability, and biocompatibility. Cubosomes offer the potential for both enhanced cellular uptake and controlled release of encapsulated payloads. Beyond cancer therapy, cubosomes have demonstrated effectiveness in wound healing, antibacterial treatments, and various dermatological applications. In this review, the authors provide an overview of the evolution of lipidic nanocarriers, spanning from conventional liposomes to solid lipid nanoparticles, with a special emphasis on the development and application of cubosomes. Additionally, it delves into recent applications and preclinical trials associated with cubosome formulations, which could be of significant interest to readers from backgrounds in nanomedicine and clinicians.

show abstract

Section: Liposomes As a Therapeutic Carriermentioning

confidence: 99%

Section: Liposomes As a Therapeutic Carriermentioning

confidence: 99%

Section: Liposomes As a Therapeutic Carriermentioning

confidence: 99%

Section: Liposomes As a Therapeutic Carriermentioning

confidence: 99%

Section: Liposomes As a Therapeutic Carriermentioning

confidence: 99%

See 3 more Smart Citations

Liposomes to Cubosomes: The Evolution of Lipidic Nanocarriers and Their Cutting-Edge Biomedical Applications

Attri,

Das,

Banerjee

et al. 2024

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

show abstract

Engineered Nanoparticles for Theranostic Applications in Kidney Repair

Jin,

Xue,

Zhang

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Kidney diseases are characterized by their intricate nature and complexity, posing significant challenges in their treatment and diagnosis. Nanoparticles (NPs), which can be further classified as synthetic and biomimetic NPs, have emerged as promising candidates for treating various diseases. In recent years, the development of engineered nanotherapeutics has focused on targeting damaged tissues and serving as drug delivery vehicles. Additionally, these NPs have shown superior sensitivity and specificity in diagnosis and imaging, thus providing valuable insights for the early detection of diseases. This review aims to focus on the application of engineered synthetic and biomimetic NPs in kidney diseases in the aspects of treatment, diagnosis, and imaging. Notably, the current perspectives and challenges are evaluated, which provide inspiration for future research directions, and encourage the clinical application of NPs in this field.

show abstract

siRNA‐based nanotherapeutics as emerging modalities for immune‐mediated diseases: A preliminary review

Sargazi

Arshad

Ghamari

et al. 2022

Cell Biology International

View full text Add to dashboard Cite

Immune-mediated diseases (IMDs) are chronic conditions that have an immunemediated etiology. Clinically, these diseases appear to be unrelated, but pathogenic pathways have been shown to connect them. While inflammation is a common occurrence in the body, it may either stimulate a favorable immune response to protect against harmful signals or cause illness by damaging cells and tissues. Nanomedicine has tremendous promise for regulating inflammation and treating IMIDs. Various nanoparticles coated with nanotherapeutics have been recently fabricated for effective targeted delivery to inflammatory tissues. RNA interference (RNAi) offers a tremendous genetic approach, particularly if traditional treatments are ineffective against IMDs. In cells, several signaling pathways can be suppressed by using RNAi, which blocks the expression of particular messenger RNAs. Using this molecular approach, the undesirable effects of anti-inflammatory medications can be reduced. Still, there are many problems with using short-interfering RNAs (siRNAs) to treat IMDs, including poor localization of the siRNAs in target tissues, unstable gene expression, and quick removal from the blood. Nanotherapeutics have been widely used in designing siRNA-based carriers because of the restricted therapy options for IMIDs. In this review, we have discussed recent trends in the fabrication of siRNA nanodelivery systems, including lipid-based siRNA nanocarriers, liposomes, and cationic lipids, stable nucleic acid-lipid particles, polymeric-based siRNA nanocarriers, polyethylenimine (PEI)-based nanosystems, chitosan-based nanoformulations, inorganic material-based siRNA nanocarriers, and hybrid-based delivery systems. We have also introduced novel siRNA-based nanocarriers to

show abstract

Dual-Regulated Functionalized Liposome–Nanoparticle Hybrids Loaded with Dexamethasone/TGFβ1-siRNA for Targeted Therapy of Glomerulonephritis

Cited by 11 publications

References 67 publications

Liposomes to Cubosomes: The Evolution of Lipidic Nanocarriers and Their Cutting-Edge Biomedical Applications

Liposomes to Cubosomes: The Evolution of Lipidic Nanocarriers and Their Cutting-Edge Biomedical Applications

Engineered Nanoparticles for Theranostic Applications in Kidney Repair

siRNA‐based nanotherapeutics as emerging modalities for immune‐mediated diseases: A preliminary review

Contact Info

Product

Resources

About